Skip to content
Angion Biomedica Corp

Angion Biomedica Corp

ANGION IS A LATE-STAGE CLINICAL COMPANY DEVELOPING SMALL MOLECULES TARGETING ACUTE ORGAN INJURY AND CHRONIC FIBROSIS

  • about
    • executive management
    • scientific advisory board
    • board of directors
  • our science
    • HGF/c-Met Pathway
    • Acute Kidney Injury
    • Acute Lung Injury
    • CNS Injury
  • pipeline
    • ANG-3777
    • ANG-3070
    • ROCK2 Inhibitor
    • CYP11B2 Inhibitor
  • Investors
    • stock information
      • stock quote & chart
    • press releases
    • events & presentations
    • financial information
      • SEC filings
    • governance
    • investor resources
      • investor contact
      • investor FAQs
      • email alerts
  • publications
  • careers
  • contact

angion publications

Renal Function Improvement Following ANG-3777 Treatment in Patients at High Risk for Delayed Graft Function After Kidney Transplantation


April 2020 – Transplantation
Posted in angion publications

Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery–Associated Acute Kidney Injury


October 2020 - Kidney Reports International
Posted in angion publications

The Effect of ANG-3777 on the Growth of c-Met Expressing Tumor Cells in Immunocompromised Mice


October 2020 - Kidney Week
Posted in angion publications

Defining a Clinically-Meaningful Difference (MCMD) in Estimated Glomerular Filtration Rate (eGFR) for Kidney Transplantation


October 2020 - Kidney Week
Posted in angion publications

Compartmental Differences Within the COL3A1 Network in Proteinuric Kidney Disease — Informing Drug Activity Using the Jaccard-Tanimoto Index


October 2020 - Kidney Week
Posted in angion publications

Design of the Graft Improvement Following Transplant (GIFT) Trial, a Phase 3 Study of ANG-3777 in Kidney Transplantation Patients with Delayed Graft Function


October 2020 - Kidney Week
Posted in angion publications

The Effect of ANG-3777 on In Vitro Cell Proliferation


October 2020 - Kidney Week
Posted in angion publications

Financial Impact of Delayed Graft Function in Kidney Transplantation


June 2020 -- Clinical Transplantation
Posted in angion publications

The Effect of ANG-3777 on Hepatocyte Growth Factor Receptor c-Met Signaling


May 2020 - American Transplant Congress
Posted in angion publications

The Evolution of Renal Graft Failure Risk: The Power of the Proximal


May 2020 - American Transplant Congress
Posted in angion publications

In vivo phosphorylation of c-MET by ANG-3777, a hepatocyte growth factor mimetic


May 2020 - American Transplant Congress
Posted in angion publications

Posts navigation

Older posts

CATEGORIES

  • RSL-HGF
  • RSL-ALI
  • Fibrosis
  • ROCKi
  • angion publications
  • RSL-AKI
  • events

CORPORATE ADDRESS

51 Charles Lindbergh Boulevard
Uniondale, NY 11553

Navigation

  • home
  • about
  • our science
  • pipeline
  • investors
  • publications
  • careers
  • contact

© 2021 Angion. All Rights Reserved.
Legal and Privacy Policy

NEW YORK | SAN FRANCISCO | BOSTON